Business Context and Reporting Period
This Form 8-K filing by Omeros Corporation covers events occurring on May 22, 2015. The report details the outcomes of the company's 2015 Annual Meeting of Shareholders and a significant regulatory milestone regarding its drug product, Omidria.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses on corporate governance and regulatory events rather than financial performance.
Material Changes and Events
Shareholder Voting Results
- Attendance: 32,389,677 shares (85.63% of eligible shares) were represented at the meeting.
- Director Elections:
- Gregory A. Demopulos, M.D.: Elected with 15,561,611 votes for, 1,353,658 withheld, and 15,474,408 broker non-votes.
- Leroy E. Hood, M.D., Ph.D.: Elected with 14,996,847 votes for, 1,918,422 withheld, and 15,474,408 broker non-votes.
- Accounting Firm Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm with 32,223,954 votes for, 147,562 against, and 18,161 abstentions.
Regulatory Approval
- The European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion for Omidria (phenylephrine and ketorolac injection) 1%/0.3%.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard regulatory context. The primary focus is the positive regulatory opinion for Omidria, which implies potential future commercialization in Europe pending final approval.
Investor Verification Checklist
- Verify the final approval status of Omidria by the European Medicines Agency following the positive opinion.
- Confirm the effective date of the new directors' terms (serving until the 2018 Annual Meeting).
- Review the attached press release (Exhibit 99.1) for specific details on the Omidria approval timeline and commercialization strategy.